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The specification of the five individual hormone-secreting cell types in the anterior pituitary requires a series of sequential
cell fate decisions. We have immortalized cells at several stages along this pathway of pituitary differentiation. Here, we
present analysis of differences in gene expression between an anterior pituitary precursor cell line, T1-1, and an immature
gonadotrope cell line, T3-1, identified by using cDNA subtraction. Messenger RNA expression of members of the
insulin-like growth factor signaling system, IGF-II and IGFBP-5, was found in the T1-1 precursor cell line, but not in the
more differentiated cell line, T3-1. This inferred stage specificity was confirmed in the mouse embryo by using in situ
hybridization on embryonic days e10.5 through e18.5. Expression of IGF-II and IGFBP-5 mRNAs was both temporally and
spatially regulated during pituitary development. IGF-II was highly expressed in the epithelium surrounding Rathke’s
pouch at e10.5, while IGFBP-5 expression was restricted to the adjacent oral epithelium. At e11.5 (represented by T1-1),
IGF-II was expressed throughout the pouch, but was coexpressed with IGFBP-5 and -subunit in the ventral portion of the
pouch epithelium. On e12.5, the two mRNAs were expressed in opposing dorsoventral (IGF-II) and ventrodorsal (IGFBP-5)
patterns, with IGF-II excluded from the rostral, -subunit-expressing region. A decrease of both mRNAs was observed at
e14.5 (equivalent to T3-1), with IGF-II levels low and IGFBP-5 concentrated in the anterior pituitary rostral tip. These
findings suggest that the timing of IGF-II expression and regulation of its accessibility by IGFBP-5 may play a role in anterior
pituitary differentiation, survival, and/or proliferation. © 2002 Elsevier Science (USA)
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The anterior pituitary is of primary importance in the
regulation of multiple physiological functions, including
metabolism, growth, and reproduction, and is a valuable
model system for temporal and tissue-specific control of
gene expression in organogenesis. During pituitary develop-
ment, five endocrine cell types arise in a specific temporal
and spatial pattern. The first discernible step in lineage
commitment (Fig. 1) is the transcription of the gene encod-
ing the common -subunit of the glycoprotein hormone
family, which includes thyroid-stimulating hormone
(TSH), luteinizing hormone (LH), and follicle-stimulating
hormone (FSH). The -subunit mRNA becomes detectable
on embryonic day e11.5 in the mouse, while expression of
the three -subunit partners of the glycoprotein hormones
emerge sequentially in clustered cell populations: TSH on
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All rights reserved.e12.5 (rostral tip of the pouch) and e14.5 (anterior pituitary),
LH on e16.5, and FSH on e17.5 (Japon et al., 1994). The
early emergence of ventral expression of -subunit mRNA
implies a common progenitor cell for the thyrotrope and
gonadotrope lineages, while later differentiation of these
individual cell types involves independent activation and
inactivation of specific regulatory and hormone genes.
Initiation of pituitary gland formation involves cell-
autonomous expression of transcription factors, such as
Rpx (Hermesz et al., 1996), Lhx3 and Lhx4 (Sheng et al.,
1997), Ptx1 (Tremblay et al., 1998), and Ptx2 (Gage et al.,
1999), in the pouch rudiment on e9. Additionally, there are
intricate interactions with secreted factors produced in
adjacent tissues that give rise to induction or repression of
gene expression. An inductive dorsal BMP4 signal from the
diencephalon is countered by a ventral boundary of Sonic
Hedgehog production in the oral ectoderm from e9 to e10.5.
From e10.5 to e12.5, dorsal expression of FGF8 originating
in the infundibulum opposes ventral expression of BMP2
from the pouch epithelium. These inductive signals estab-1438. E-mail: pmellon@ucsd.edu.319
lish zones of cell-autonomous transcription in the differen-
tiating Rathke’s pouch (Treier et al., 1998) from e10.5 to
e14.5. For reference, the line drawings at the bottom of Figs.
5 and 6 depict embryonic pituitary morphology. Several
homeodomain transcription factors are expressed primarily
dorsally, Nkx3.1, Six-3, and Prop-1, or ventrally, Brn-4,
Isl-1, and P-Frk (Treier et al., 1998). Ultimately, distinct
zones of combinatorial expression are created by overlap-
ping expression of Pax6 (dorsal), Pit1 (intermediate), and
GATA2 (ventral) (Kioussi et al., 1999), and these zones help
to specify the distinct cell types found in the fully differen-
tiated organ.
Targeted tumorigenesis in transgenic mice has led to the
establishment of cell lines representing several stages of
differentiation in the anterior pituitary (Alarid et al., 1996;
Windle et al., 1990). Utilization of the 5 regulatory regions
of the human - and -subunit glycoprotein hormone genes
driving expression of the SV40 T-antigen oncogene pro-
duced pituitary tumors in multiple transgenic mouse lines.
Dispersion of isolated tumors generated the T1-1, T3-1,
LT-2, and TT1 clonal cell lines. These cell lines express
hormone subunits and receptors characteristic of gonado-
tropes or thyrotropes at specific developmental stages.
Figure 1 shows their proposed positions in the gonadotrope
and thyrotrope lineages, based on gene expression patterns,
along with the corresponding day of embryonic mouse
development. Here, we compare the genes expressed in the
T1-1 vs T3-1 cell lines to identify factors specifically up-
or down-regulated during the progression of lineage com-
mitment. The T1-1 cell line potentially represents a
multipotent precursor to the thyrotrope and gonadotrope
lineages, while the T3-1 cell line represents a committed
immature gonadotrope, based on its expression of the
gonadotropin-releasing hormone receptor (GnRH receptor)
and the Steroidogenic Factor-1 (SF-1) transcriptional regu-
latory protein (Alarid et al., 1996). SF-1 is known to be
unique to the gonadotrope lineage within the anterior
pituitary (Barnhart and Mellon, 1994; Ingraham et al.,
1994).
Using subtractive hybridization between T1-1 and
T3-1 cDNA libraries, we have cloned genes that are
specifically expressed in the T1-1 precursor, but not in the
more differentiated T3-1 cell line. Two of these genes,
insulin-like growth factor-II (IGF-II) and insulin-like growth
factor binding protein-5 (IGFBP-5) are interacting members
of the IGF signaling pathway. IGF-II is a primary growth
factor during early embryogenesis that signals through
binding to the IGF-I receptor and the insulin receptor (Baker
et al., 1993; Louvi et al., 1997; Morrione et al., 1997). In
addition, its accumulated protein levels are regulated by the
IGF-II receptor, also known as the Mannose-6-phosphate
receptor. IGF-II and IGF-I have overlapping receptor binding
profiles and functions, with multiple levels of redundancy
in the system. IGF-II is implicated in the proliferation and
differentiation of myoblasts (Bach et al., 1995; Florini et al.,
1991), in osteoblast differentiation during bone repair
(Linkhart et al., 1996), and in the cytodifferentiation of
granulosa cells in the human ovary (Erickson and Danforth,
1995).
The activities of IGF-I and IGF-II can be modulated by an
ever-growing group of IGF-binding proteins, whose activi-
ties are, in turn, regulated by the IGFBP proteases. Depend-
ing on the cellular context, IGF-II action can be inhibited by
IGFBP-5 binding (Ewton and Florini, 1995), or potentiated if
the binding protein is also associated with extracellular
matrix components (Jones et al., 1993). IGFBP-5 is capable
of stimulating both myoblast differentiation and prolifera-
tion (Florini et al., 1996) and is downregulated by BMPs
during osteoblast differentiation (Gabbitas and Canalis,
1995; Yeh et al., 1998). IGFBP-5 also appears to stimulate
apoptosis during atresia of ovarian follicles (Erickson and
Danforth, 1995) and during mammary involution (Tonner
et al., 1997). We find that IGF-II and IGFBP-5 are expressed
in a complementary pattern on the dorsoventral axis during
anterior pituitary differentiation, where they are likely




All cell lines (Alarid et al., 1996; Windle et al., 1990) were
cultured in DMEM (Cellgro, Mediatech, Inc., Herndon, VA) supple-
mented with 10% fetal bovine serum (Omega Scientific Inc.,
Tarzana, CA) at 37°C in 5% CO2. Cells were harvested at 70–80%
confluency for RNA isolation.
Subtractive Hybridization
RNA was isolated from the immortalized T3-1 and T1-1 cell
lines by guanidinium extraction (Chomczynski and Sacchi, 1987)
and then poly(A) selected (Promega PolyATtract). cDNA plasmid
libraries were constructed from this enriched mRNA population by
using the Gibco BRL Superscript Plasmid System, which clones
inserts in a known orientation. The subtractive cDNA libraries
were made by hybridizing cDNA from one cell line (Tester) with an
excess of biotinylated cDNA from the other cell line (Driver) (Hara
et al., 1994). The separation of cDNA unique to the Tester
population was accomplished by binding all biotinylated com-
plexes with streptavidin and subsequently extracting these biotin-
avidin complexes with phenol. Thus, only Tester-specific cDNA,
which is unable to heterodimerize with the excess biotinylated
Driver cDNA, remains in the aqueous phase.
Subtractive Library Screening
The cDNA from the aqueous phase of the subtraction was
subcloned into a Kanamycin vector (pBKCMV from Stratagene) for
further analysis. Plasmid DNA from individual clones was isolated
by alkaline lysis miniprep (Birnboim, 1983). Clones were digested
with SalI and NotI to identify insert size, and inserts purified by
electroelution from agarose gel slices were used as Northern blot
probes. Replicate formaldehyde gels were made with 10 g per lane
of total RNA from the T3-1 and T1-1 cell lines and blotted on
GeneScreen (NEN). The purified inserts were 32P labeled by random
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priming (Feinberg and Vogelstein, 1983) and used to probe the blots.
Any clones that showed expression specific to the T3-1 or T1-1
cell line were sequenced by the dideoxy method (Sanger et al.,
1977). Sequence data from the 5 and 3 ends of the inserts were
analyzed by BLAST (Altschul et al., 1990) search of known DNA
sequences. Interesting clones that showed cell-line-specific expres-
sion by Northern blotting were also tested for appropriate develop-
mental expression by in situ hybridization to day e10.5 through
e18.5 mouse embryos.
Northern Blot Analysis
Duplicate formaldehyde gels were made with 10 g per lane of
total RNA that had been isolated by using TRI Reagent (Sigma).
Gels were blotted on GeneScreen (NEN). Gel-purified cDNA
fragments were 32P-labeled by random priming (Stratagene Prime-
It) and used to probe the blots. The gels and blots were ethidium
bromide-stained to check for even loading, and both blots were
probed with GAPDH to ensure that all RNA samples were intact
and that the blots were identical.
Affymetrix Gene Chip Analysis
Gene Chip analysis of mRNA expression was performed by the
Gene Chip Core Facility at the UCSD Cancer Center. The cell lines
used for the analysis were cultured in the same manner as those
used for the Northern blot analysis. Total RNA was harvested by
using the Qiagen Rneasy kit. Reverse transcription, second-strand
synthesis, and probe generation were all performed by using the
standard Affymetrix protocol (Affymetrix, Santa Clara, CA). In like
fashion, Mouse Genome U74A GeneChips (Affymetrix) were hy-
bridized, washed, and scanned according to the standard Af-
fymetrix protocol. Data were analyzed with the Affymetrix GENE-
CHIP EXPRESSION ANALYSIS software (version 3.1), or
Microsoft Excel. All chips were scaled to 2500 by using global
scaling so that separate chips could be accurately compared. Data
shown are from two chip experiments, side-by-side.
Embryo Sections
Matings were set up in the late afternoon, with embryonic day
0.5 set to the following day at noon (assuming coitus at midnight).
Males were removed by noon of the following day and the female
sacrificed on the appropriate day postcoitum. Embryos were re-
moved into neutral-buffered formalin for 4 days of fixation with 8%
sucrose added on the last day. For embryos older than e14.5, only
the heads were fixed. Fixed embryos were embedded in OCT
(Aldrich) and quick-frozen in a hexapentane dry ice bath. Five-
micron sagittal sections were cut at 20°C at on a cryostat by the
UCSD Histology Core.
In Situ Hybridization
We performed in situ analyses by hybridizing 35S or 33P antisense
RNA probes from cloned cDNAs with 5-m sagittal sections of
mouse embryos ages e10.5 to e18.5. The hybridization was per-
formed using a protocol developed for use with rat brains (Simmons
et al., 1989). Slides were dipped in photographic emulsion (Kodak
NTB2) and exposed from 10 days to 5 weeks, depending on the
probe used. After developing, the slides were stained with bis-
benzamide (Sigma), a blue nuclear stain. Adjacent sections were
used for the various probes within one experiment. Slides were
photographed by using dark field and UV illumination at 100
magnification.
RESULTS
Subtractive Hybridization and Library Screening
To identify gonadotrope lineage stage-specific genes, we
performed subtractive hybridization between two cell lines
representing different stages of pituitary gonadotrope differ-
entiation. We chose the T1-1 cell line, representing an
uncommitted precursor, and the T3-1 line, representing
the earliest level of commitment in the lineage (see Fig. 1).
Using subtractive hybridization to remove the sequences
common to both cell lines (Hara et al., 1994), we prepared
selected plasmid libraries of T1-1- and T3-1-specific
cDNAs. The cessation of gene transcription can be just as
important in development as its onset (Levine and Manley,
1989), so we performed the subtraction in both directions.
From the library containing genes expressed in the T1-1
precursor line and absent from the more differentiated line,
we identified cDNAs for two interacting proteins, IGF-II
and IGFBP-5. Both genes were cloned multiple times and
had 100% homology when compared with the public se-
quence databases using the BLAST algorithm. In further
analysis of this library of selected cDNA clones, the iso-
lated plasmid inserts were individually radiolabeled and
used to probe Northern blots containing total RNA from
the T1-1 and T3-1 cell lines. Clones that showed appro-
priate differential expression between these two cell lines
(data not shown) were chosen for further investigation.
RNA Expression in Pituitary Cell Lines
To determine the pattern of mRNA expression in a
variety of pituitary cell lines, more extensive Northern
blots were performed. Figure 2 shows high-level expression
of the IGF-II and IGFBP-5 genes in T1-1 precursor cells and
the apparent absence of expression in T3-1 cells, confirm-
ing the original screening Northern blots. Additionally, we
find that IGF-II is expressed in the TT1 thyrotrope cell
line. IGFBP-5 is also highly expressed in the LT2 mature
gonadotrope line and to a lesser extent in the TT1 (thyro-
trope) and AtT20 (corticotrope) cell lines as well as adult
pituitary.
To augment our subtractive hybridization results, we
have subsequently moved toward comparing gene expres-
sion in the various cell lines using gene chip technology.
Analysis utilizing Affymetrix gene chips has confirmed the
Northern expression data for clones that were isolated in
the subtractive libraries. Thus, the Northern expression
profile in Fig. 2 is consistent with the results from two
Affymetrix experiments using mouse genome chips (U74A)
with the T1-1, T3-1, and LT2 cell line cDNAs as target
(Fig. 3).
We next examined the expression of other members of
the IGF signaling pathway by Northern blot analysis. Ex-
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pression of IGF-I was not detectable on Northern blots in
any of the gonadotrope-derived cell lines but was seen in
the rat GH4 somatomammotrope line (Fig. 2). In addition,
we assessed the presence of several other known IGF-
binding protein mRNAs: IGFBPs 1, 2, 3, 4, and 6, which
were also undetectable in the Northern assay (data not
shown). However, we did detect expression of the IGF-I
receptor, IGF-II receptor, and the insulin receptor (all of
which can bind to IGF-II). Figure 4 shows Northern blots
probed with the IGF-I and IGF-II receptors and indicates
that the T1-1 and T3-1 cell lines contain the necessary
components for IGF-II signaling.
IGF-II Is Expressed in Rathke’s Pouch and IGFBP-5
Is Excluded at e10.5
To determine whether the stage-specific expression ob-
served in the cell lines was an accurate representation of the
in vivo patterns, we used the IGF-II and IGFBP-5 cDNA
clones to make anti-sense RNA for in situ hybridization
with embryonic mouse pituitaries. Using 5-m sagittal
sections from mouse embryos at various ages, we correlated
the expression patterns of IGF-II and IGFBP-5 with those of
known anterior pituitary markers. On e10.5, the primordial
pituitary is an invagination in the oral ectoderm known as
Rathke’s pouch. As shown in Fig. 5, the -subunit of the
gonadotropin hormones is not yet expressed in the pouch
epithelium, but IGF-II is strongly expressed in the pouch
epithelium as well as the bordering oral ectoderm. IGFBP-5
is expressed in the oral ectoderm but is excluded from the
pouch epithelium, exhibiting much the same zonal pattern
as Sonic hedgehog (Shh) (Treier et al., 1998).
Complementary Dorsal/Ventral Expression of IGF-
II and IGFBP-5
Rathke’s pouch pinches off and is separated from the oral
ectoderm by e11.5 when -subunit expression begins in a
small subset of the ventral pouch epithelial cells (Fig. 5). At
FIG. 1. Immortalized cell lines representing discrete stages of
pituitary development. Pituitary cell lines produced by targeted
tumorigenesis are represented by ovals. The name of the cell line is
noted beneath the oval and the corresponding embryonic age is
noted above. Specific mRNAs expressed by cell lines are noted
within the ovals ( represents alpha subunit of the glycoprotein
hormones).
FIG. 2. Northern blot analysis of IGF-II and IGFBP-5 mRNAs.
Replicate Northern blots containing 10 g per lane of total RNA
from cell lines or adult pituitary were probed with cDNA inserts
radiolabeled with 32P by random priming. 28s and 18s label the
positions on the Northern blot of the 28s and 18s ribosomal RNA
bands whose sizes correspond to 5 and 2 kb, respectively. The
lanes are labeled across the top with the name of the cell line or pit
(for adult pituitary). The name of the cDNA probe used for each
blot is found to the left.
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this stage, IGF-II, which was previously uniformly ex-
pressed around the pouch, now exhibits more robust expres-
sion in the dorsal region pouch epithelium. Likewise,
IGFBP-5 shows a complementary ventralized expression. A
cell model for the e11.5 stage is represented by the T1-1
cell line, which expresses -subunit, IGF-II, and IGFBP-5. A
population of cells in the ventral portion of the pouch
epithelium does appear to coexpress these mRNAs.
By e12.5 (Fig. 5), the epithelium has proliferated and a
rostral group of differentiating cells has separated from the
remainder of the pouch. Gonadotropin -subunit expres-
sion is confined to this rostral area where a subset of cells
also express the TSH- subunit. IGFBP-5 RNA is concen-
trated in the rostral, -subunit-expressing region, while
maintaining primarily ventral expression in the pouch
epithelium. Conversely, IGF-II is excluded from this differ-
entiating region where -subunit is expressed, and exhibits
a more dorsal concentration of expression around the pouch
itself. The complementarity of the IGF-II and IGFBP-5
patterns is striking, especially with regard to the rostral
region and their negative and positive correlations with
-subunit expression. It suggests that the two IGF gene
products may have opposing functions in pituitary develop-
ment that are reflected in their opposing patterns of mRNA
expression.
IGF-II and IGFBP-5 Expression Late in Anterior
Pituitary Development
By e14.5, the morphology of the anterior pituitary more
closely resembles that of the adult pituitary, with distin-
guishable anterior, intermediate, and posterior domains
emerging (Fig. 6). At this point in development, the mul-
tiple cell types in the anterior lobe are still segregated into
clusters. The -subunit probe marks cells of both gonado-
trope and thyrotrope lineages in the ventral portion of the
nascent anterior pituitary. The TSH -subunit pattern is
similar, but less robust in the ventral posterior area, since
the gonadotrope cells do not express TSH-. As seen in the
GnRH receptor panel of Fig. 6, only the posterior group of
cells that is positive in the -subunit panel is also positive
for GnRH receptor and thus destined to become gonado-
tropes. The positive -subunit expression in the anterior-
most cells (the rostral tip) is due to a Pit-1-independent
thyrotrope population (Bockman et al., 1997). This rostral
region also expresses high levels of IGFBP-5. Low-level
expression of IGFBP-5 is also seen in the region of the
anterior pituitary. IGF-II levels are low in the anterior
pituitary but high in surrounding tissues (Fig. 6).
By e18.5, the anterior, intermediate and posterior lobes of
the pituitary are established. IGF-II expression in the ante-
rior pituitary tissues has become undetectable, while
IGFBP-5 shows barely detectable expression. IGFBP-5 is
highly expressed only in the rostral tip of the anterior
pituitary, where the rostral thyrotropes reside, with faint
spotty expression in rest of the anterior pituitary. Low level
expression is also seen in the intermediate and posterior
pituitary.
FIG. 3. Affymetrix Gene Chip expression analysis. The data
shown are from two experiments with U74A mouse chips. In each
case, the first bar of a color (labeled #1) represents the first
experiment and the second bar (labeled #2) represents a second
independent experiment. Within one experiment, RNA from the
different cell lines was used to make labeled target DNA and
identical chips were probed in parallel and analyzed together.
Different RNA samples were used to probe the chips in the second
experiment. The Average Difference Values (intensity of Perfect
Match probe pairs minus intensity of the Mismatch probe pairs) are
plotted on a log scale and negative values were set to one. The
minimum value shown on the y-axis is set to 1000, as values less
than these are usually called “expression absent” by the Affymetrix
software. Thus, the absence of a bar indicates a value below 1000
and all three cell lines were analyzed with all four probes. Com-
parisons of Average Difference Values are quantitative only for the
same probe between chips probed with different RNA samples.
FIG. 4. Northern blotting for IGF receptors. Replicate Northern
blots containing 10 g per lane of total RNA from the T3-1 and
T1-1 cell lines were probed with radiolabeled cDNA fragments
from the mouse IGF-I or IGF-II receptors. 28s and 18s labels the
position on the blot of the 28s and 18s ribosomal RNA bands whose
sizes correspond to 5 and 2 kb, respectively. The mouse IGF-I
receptor band is at approximately 11 kb and the IGF-II receptor
band is at 9 kb.
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FIG. 5. In situ hybridizations of e10.5, e11.5, and e12.5 mouse embryos. Panels show in situ hybridization of 5-m sagittal sections of
mouse embryos with radiolabeled anti-sense RNA probes. The embryo ages are shown at the top of each column, and the RNA probe
utilized is shown to the right of each row. The blue nuclear staining is bis-benzamide and is used to show the tissue morphology. The white
color indicates probe hybridization and is generated by dark-field imaging of exposed silver grains. In all panels, anterior is toward the left
of the page and dorsal is toward the top of the page. In the line drawings below the photographs, a feature is shaded with the same color
as its descriptor, with the exception of the diencephalon. The abbreviation “DI” denotes diencephalons and is located directly over that
region. The abbreviation “INF” denotes infundibulum and is shaded the color of that region.
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DISCUSSION
Cell fate decisions in organogenesis are produced both by
intrinsic transcription factors and by extrinsic influences
from growth factors and morphogens. We have cloned two
members of the insulin-like growth factor signal transduc-
tion family from a subtractive library in which we selected
for genes that were highly expressed early in pituitary
development and decreased by the stage of gonadotrope
commitment. IGFBP-5 is known to inhibit or potentiate
IGF-II activity, depending on the cellular context (Ewton
and Florini, 1995; Jones et al., 1993). Both IGF-II and
IGFBP-5 mRNAs have been previously detected in the rat
embryonic pituitary, but these studies were not focused on
pituitary development and did not examine the same time
points (Green et al., 1994; Stylianopoulou et al., 1988).
Based on in situ hybridization analyses in mouse embryos,
we show that IGF-II and IGFBP-5 mRNAs are expressed in
the developing pituitary in unique and opposing dorsal–
ventral patterns. Because many other transcription and
growth factor mRNAs are also expressed in dorsal–ventral
patterns in the anterior pituitary (for review, see Kioussi et
al., 1999), we suggest that IGF-II and IGFBP-5 are also
involved in the establishment of zones of differentiation. It
is of particular interest that IGFBP-5 strongly colocalizes
with -subunit, which is thought to mark the differentiat-
ing population at embryonic days e11.5 and e12.5. In turn,
IGF-II is stringently excluded from this differentiation cen-
ter on e12.5, not only by a lack of autonomous expression,
but possibly by the high concentration of IGFBP-5 in that
region. Additionally, IGFBP-5 may play a role in the rostral
thyrotrope region where it is coexpressed with TSH at
e14.5 and e18.5. These rostral thyrotropes are purported to
be a transient population in mice, with a loss of either cells
or TSH expression by adulthood (Lin et al., 1994). IGFBP-5
has been implicated in the initiation of apoptosis in mam-
mary involution (Flint et al., 2000) and could play a similar
role in the disappearance of the rostral thyrotrope popula-
tion.
In Fig. 2, the Northern analysis demonstrates IGFBP-5
mRNA expression in LT2, the mature gonadotrope cell
line, in contrast to the faint expression detected in the
anterior lobe by in situ hybridization of e18.5 embryos.
Northern blot analysis is known to be more sensitive than
in situ under most conditions, which may explain the
differences. Alternatively, it may be that IGFBP-5 is induc-
ible in the mature gonadotrope and that the LT2 cells
represent this state. On the other hand, the percentage of
gonadotropes in the anterior pituitary at this later stage of
development is small (see the FSH panel in Fig. 6), and this
FIG. 6. In situ hybridizations of e14.5 and e18.5 mouse embryos.
Panels show in situ hybridization of 5-m sagittal sections of
mouse embryos with radiolabeled anti-sense RNA. The embryo
ages are shown at the top of each column and the RNA probe used
is shown in each panel. The blue nuclear staining is bis-benzamide
and is used to show the tissue morphology. The white color
indicates probe hybridization and is generated by dark-field imag-
ing of exposed silver grains. All slides were oriented with the
anterior of the mouse head at the left and dorsal at the top. In the
line drawings below the figures, labels are directly over the de-
scribed region, with the exception of “inter. lobe” and “INF”,
which are offset and shaded the same color as the described regions.
The abbreviation “INF” denotes infundibulum and “inter. lobe”
denotes intermediate lobe.
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scarcity of gonadotropes might result in the faint signal in
the anterior lobe. Low level IGFBP-5 expression is seen in
the AtT20 corticotrope cell line, though there is no obvious
expression in the corresponding dorsal region of the anterior
pituitary at e18.5. Further studies using in situ hybridiza-
tion with adult pituitaries show that IGFBP5 is not ex-
pressed in either the anterior, intermediate, or posterior
lobes (data not shown), though there is a faint band in the
Northern for adult pituitary, again pointing out differences
in sensitivity between these two methodologies.
IGF-II is expressed in multiple differentiating organ sys-
tems, where its effects on differentiation can be stimulatory
or antagonistic. In muscle cell culture, an autocrine loop of
IGF-II expression can drive either proliferation or differen-
tiation, depending on conditions (Florini et al., 1991). It is
interesting that IGF-II differentiation in the muscle system
is biphasic in nature with differentiation stimulated at low
concentrations and inhibited at higher concentrations (Flo-
rini et al., 1986). IGFBP-5 expression in muscle is dramati-
cally increased during differentiation and its effects on IGF
action can also be either stimulatory or inhibitory, depend-
ing on the conditions used (Florini et al., 1996). In the
human ovary, IGF-II stimulates the cytodifferentiation of
granulosa cells by opposing the action of activin, a TGF-
family member which is also important for pituitary gona-
dotrope function. IGFBP-5 appears to antagonize IGF activ-
ity and is strongly expressed in atretic follicles (Erickson
and Danforth, 1995). In bone cell cultures, BMP-7 and
BMP-2 have been shown to impact IGF-II and IGFBP-5
expression (Gabbitas and Canalis, 1995; Yeh et al., 1998),
with IGF-II and BMP-7 cooperating to stimulate differentia-
tion (Yeh et al., 1997). During lung branching morphogen-
esis and cell lineage differentiation, both IGF and BMP
signaling systems play an inductive role (Warburton et al.,
2000). In the embryonic pituitary, BMP-4 is expressed
dorsally, while BMP-2 is expressed ventrally. Based on other
systems, these BMP proteins are candidates for interaction
with IGF-II and IGFBP-5, at the level of expression or
function.
Due to extreme redundancy in the IGF signaling system,
it is difficult to clearly determine what the roles of IGF-II
and IGFBP-5 might be in pituitary development. Mouse
null mutations of many components of IGF signaling have
been created, and it has been observed that even where one
protein plays a clear role in a particular system, phenotypes
are less severe than expected in the knockout animals. This
phenomenon is most likely due to compensation by family
members with overlapping binding specificities. This inter-
pretation is supported by the observation that animals with
multiple null mutations exhibit more severe phenotypes
(Baker et al., 1993; Liu et al., 1993; Wood et al., 2000). IGF-I
and IGF-II signal primarily via the IGF-I receptor; however,
IGF-II can also signal through the insulin receptor and
perhaps another unidentified receptor (Baker et al., 1993).
IGF-II is the primary early embryonic growth factor in this
system, since the onset of IGF-I expression is not until
e13.5 (Baker et al., 1993). Levels of IGF-II protein are
carefully regulated through gene imprinting (only the pater-
nal copy is expressed) and through degradation after IGF-II
receptor (mannonse-6-phosphate receptor) binding. IGF-II
knockout animals have a birth weight that is 60% of wild
type and are fertile, indicating the presence of a functional
pituitary (Baker et al., 1993). However, IGF-I may be com-
pensating for the lack of IGF-II in these animals. Overabun-
dance of IGF-II resulting from deletion of the IGF-II/
mannose-6-phosphate receptor results in low viability and
reduced fertility (25% infertility) in animals whose gonads
are phenotypically normal (Ludwig et al., 1996). In the case
of IGFBP2 null animals, which are the only IGFBP deletion
published, compensatory up-regulation of serum protein
levels is seen for several other IGFBPs (Wood et al., 2000).
In an attempt to determine whether IGF-II misexpression
in the embryonic anterior pituitary might be inhibitory to
gonadotrope or thyrotrope differentiation, we created a
transgenic mouse line. In these mice, IGF-II cDNA expres-
sion was driven by the human 5.5-kb -subunit pituitary-
specific promoter, whose earliest onset of expression is
normally e11.5 (see Fig. 5). This transgene causes IGF-II to
be coexpressed in cells that express the -subunit of the
glycoprotein hormones, where it is normally excluded after
e11.5. Surprisingly, although these animals expressed the
transgene in the adult pituitary, they were fertile. To
determine whether pituitary development may have been
delayed in these transgenic mice, we examined embryos
heterozygous for the transgene. Using in situ hybridization
at e12.5, e14.5, and e18.5, we found normal expression of all
gonadotrope and thyrotrope markers examined (data not
shown). However, transgene expression was not detectable
by in situ hybridization at e12.5, but was robust by P1 (data
not shown). It is probable that early transgene expression
levels were insufficient to alter normal developmental
patterns, or that expression levels of other components of
the IGF signaling system, such as the IGF-II receptor, may
have been altered to compensate for the IGF-II misexpres-
sion. Based on data from IGF-II action in muscle cell culture
(Florini et al., 1986) and the multiple mechanisms for
controlling IGF-II levels, concentration is very important
with respect to effects on differentiation. It may be that
IGF-II/IGFBP-5 expression profiles are critical to pituitary
differentiation primarily at a time prior to the onset of
strong expression of the transgene (e12.5 and earlier). It is
clear that differential expression of IGF-II and IGFBP-5
occurs from e10.5 through e12.5 (see Fig. 5), so the onset of
strong transgene expression could be too late for the disrup-
tion of the developmental program. Also, if IGFBP-5 is
antagonistic to IGF-II function, perhaps the IGF-II transgene
expression levels were insufficient to overcome IGFBP-5
activity.
In summary, we have characterized the mRNA expres-
sion of a pair of interacting signaling factors, IGF-II and
IGFBP-5, that are highly and specifically expressed early
during pituitary development. Expression of these two
genes is carefully orchestrated in complementary patterns
on the dorsoventral axis at days 11.5 and 12.5 of embryo-
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genesis. IGF-II is highly expressed in the dorsal pouch
epithelium, paralleling the inhibitory BMP4 and FGF8
dorsal to ventral signaling from the diencephalon and
infundibulum (Treier et al., 1998). IGFBP-5 is highly con-
centrated in the rostral tip of the differentiating pouch and
shows a ventral to dorsal pattern of expression that corre-
sponds to the BMP2 inductive signal (Treier et al., 1998). At
embryonic day e12.5, there is a striking exclusion of IGF-II
from the differentiating anterior-pituitary cells in the ros-
tral tip, with strong expression of both IGBP-5 and the
glycoprotein hormone -subunit in this region. Due to the
complexity, concentration dependence, and redundancy of
the IGF signaling system, it is difficult to determine the
effects of overexpression or deletion of these factors with-
out ambiguity. Further investigation will be required to
understand the role of IGF signaling in the developmental
cascade of dorsalizing and ventralizing factors in the em-
bryonic pituitary.
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